Dear Dr. Cook:

The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) for the ProACT™ Adjustable Continence Therapy for Men. This device is indicated for the treatment of adult men who have stress incontinence arising from intrinsic sphincter deficiency of at least twelve months duration following radical prostatectomy or transurethral resection of the prostate (TURP) and who have failed to respond adequately to conservative therapy. We are pleased to inform you that the PMA is approved. You may begin commercial distribution of the device in accordance with the conditions of approval described below.

The sale and distribution of this device are restricted to prescription use in accordance with 21 CFR 801.109 and under section 515(d)(1)(B)(ii) of the Federal Food, Drug, and Cosmetic Act (the act). The device is further restricted under section 515(d)(1)(B)(ii) of the act insofar as the labeling must specify the specific training or experience practitioners need in order to use the device. FDA has determined that these restrictions on sale and distribution are necessary to provide reasonable assurance of the safety and effectiveness of the device. Your device is therefore a restricted device subject to the requirements in sections 502(q) and (r) of the act, in addition to the many other FDA requirements governing the manufacture, distribution, and marketing of devices.

Expiration dating for this device has been established and approved at five years for the ProACT implant.

Continued approval of this PMA is contingent upon the submission of periodic reports, required under 21 CFR 814.84, at intervals of one year (unless otherwise specified) from the date of approval of the original PMA. Two copies of this report, identified as “Annual Report” and
bearing the applicable PMA reference number, should be submitted to the address below. The Annual Report should indicate the beginning and ending date of the period covered by the report and should include the information required by 21 CFR 814.84. This is a reminder that as of September 24, 2014, class III devices are subject to certain provisions of the final UDI rule. These provisions include the requirement to provide a UDI on the device label and packages (21 CFR 801.20), format dates on the device label in accordance with 21 CFR 801.18, and submit data to the Global Unique Device Identification Database (GUDID) (21 CFR 830 Subpart E). Additionally, 21 CFR 814.84 (b)(4) requires PMA annual reports submitted after September 24, 2014, to identify each device identifier currently in use for the subject device, and the device identifiers for devices that have been discontinued since the previous periodic report. It is not necessary to identify any device identifier discontinued prior to December 23, 2013. For more information on these requirements, please see the UDI website, http://www.fda.gov/udi.

In addition to the above, and in order to provide continued reasonable assurance of the safety and effectiveness of the device, the Annual Report must include, separately for each model number (if applicable), the number of devices sold and distributed during the reporting period, including those distributed to distributors. The distribution data will serve as a denominator and provide necessary context for FDA to ascertain the frequency and prevalence of adverse events, as FDA evaluates the continued safety and effectiveness of the device.

In addition to the Annual Report requirements, you must provide the following data in post-approval study (PAS) reports for the PAS listed below.

**OSB Lead PMA Post-Approval Study – ProACT Post-Approval Study:** The Office of Surveillance and Biometrics (OSB) has the lead for studies initiated after device approval. On July 28, 2015 (by e-mail) you agreed to conduct a post-approval study as follows:

- The ProACT PAS is a 5-year prospective, open-label, multi-center study designed to evaluate the long-term incidence of urethral stricture and device erosion after ProACT implantation. In addition, the study will evaluate whether treatment with ProACT affects clinical outcomes after subsequent SUI therapies.

- In this new enrollment study, 145 subjects will be enrolled at 5 to 7 sites in the U.S and, with an estimated 20% screen failure rate, 116 subjects are expected to be successfully implanted with the ProACT device. Subject follow-up will occur at 6 weeks, 6 months, and 1, 2, 3, 4, and 5 years post-treatment. With an estimated 20% attrition rate over 5 years of follow-up, 93 subjects are expected to complete the 5-year visit.

- Data will be collected on the following study outcomes: cumulative incidence of urethral strictures over 5 years of follow-up; cumulative incidence of device erosions over 5 years of follow-up; Incontinence Quality of Life (I-QoL) Questionnaire over 5 years of follow-up; and the choice of subsequent SUI therapy(ies) post ProACT treatment.

You will submit PAS Progress Reports every six months during the first two years of the study
and annually thereafter. Two copies for each study, identified as “OSB Lead PMA Post-Approval Study Report” and bearing the applicable PMA reference number, should be submitted to the address below.

Within 30 days of your receipt of this letter, you must submit a PMA supplement that includes a complete protocol of your post-approval study described above. Your PMA supplement should be clearly labeled as an “OSB Lead PMA Post-Approval Study Protocol” as noted above and submitted in triplicate to the address below. Please reference the PMA number above to facilitate processing.

Be advised that the failure to conduct any such study in compliance with the good clinical laboratory practices in 21 CFR part 58 (if a non-clinical study subject to part 58) or the institutional review board regulations in 21 CFR part 56 and the informed consent regulations in 21 CFR part 50 (if a clinical study involving human subjects) may be grounds for FDA withdrawal of approval of the PMA. In addition, the results from any post approval study should be included in the labeling as these data become available. Any updated labeling must be submitted to FDA in the form of a PMA Supplement. For more information on post-approval studies, see the FDA guidance document entitled, “Procedures for Handling Post-Approval Studies Imposed by PMA Order” (http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm070974.htm).

Before making any change affecting the safety or effectiveness of the device, you must submit a PMA supplement or an alternate submission (30-day notice) in accordance with 21 CFR 814.39. All PMA supplements and alternate submissions (30-day notice) must comply with the applicable requirements in 21 CFR 814.39. For more information, please refer to the FDA guidance document entitled, “Modifications to Devices Subject to Premarket Approval (PMA) - The PMA Supplement Decision-Making Process” (www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm089274.htm).

You are reminded that many FDA requirements govern the manufacture, distribution, and marketing of devices. For example, in accordance with the Medical Device Reporting (MDR) regulation, 21 CFR 803.50 and 21 CFR 803.52, you are required to report adverse events for this device. Manufacturers of medical devices, including in vitro diagnostic devices, are required to report to FDA no later than 30 calendar days after the day they receive or otherwise becomes aware of information, from any source, that reasonably suggests that one of their marketed devices:

1. May have caused or contributed to a death or serious injury; or

2. Has malfunctioned and such device or similar device marketed by the manufacturer would be likely to cause or contribute to a death or serious injury if the malfunction were to recur.
Additional information on MDR, including how, when, and where to report, is available at
www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

In accordance with the recall requirements specified in 21 CFR 806.10, you are required to
submit a written report to FDA of any correction or removal of this device initiated by you to:
(1) reduce a risk to health posed by the device; or (2) remedy a violation of the act caused by the
device which may present a risk to health, with certain exceptions specified in 21 CFR
806.10(a)(2). Additional information on recalls is available at

CDRH does not evaluate information related to contract liability warranties. We remind you;
however, that device labeling must be truthful and not misleading. CDRH will notify the public
of its decision to approve your PMA by making available, among other information, a summary
of the safety and effectiveness data upon which the approval is based. The information can be
found on the FDA CDRH Internet Home Page located at
www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/
PMAApprovals/default.htm. Written requests for this information can also be made to the Food
and Drug Administration, Dockets Management Branch, (HFA-305), 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852. The written request should include the PMA number or docket
number. Within 30 days from the date that this information is placed on the Internet, any
interested person may seek review of this decision by submitting a petition for review under
section 515(g) of the act and requesting either a hearing or review by an independent advisory
committee. FDA may, for good cause, extend this 30-day filing period.

Failure to comply with any post-approval requirement constitutes a ground for withdrawal of
approval of a PMA. The introduction or delivery for introduction into interstate commerce of a
device that is not in compliance with its conditions of approval is a violation of law.

You are reminded that, as soon as possible and before commercial distribution of your device,
you must submit an amendment to this PMA submission with copies of all approved labeling in
final printed form. Final printed labeling that is identical to the labeling approved in draft form
will not routinely be reviewed by FDA staff when accompanied by a cover letter stating that the
final printed labeling is identical to the labeling approved in draft form. If the final printed
labeling is not identical, any changes from the final draft labeling should be highlighted and
explained in the amendment.

All required documents should be submitted in 6 copies, unless otherwise specified, to the
address below and should reference the above PMA number to facilitate processing.

U.S. Food and Drug Administration
Center for Devices and Radiological Health
PMA Document Control Center – WO66-G609
10903 New Hampshire Avenue
If you have any questions concerning this approval order, please contact Mr. Robert De Luca at (301) 796-6551 or Robert.DeLuca@fda.hhs.gov.

Sincerely yours,

Herbert P. Lerner -S

for

Benjamin R. Fisher, Ph.D.
Director
Division of Reproductive, Gastro-Renal, and Urological Devices
Office of Device Evaluation
Center for Devices and Radiological Health